Loading organizations...
§ Private Profile · Mountain View, CA, USA
Perlegen Sciences is a company.
Key people at Perlegen Sciences.
Perlegen Sciences identifies genetic variations to advance pharmacogenomics. The company leverages sophisticated microarray technology, a spin-off from Affymetrix, for rapid, cost-effective analysis of millions of unique genetic differences. This approach profiles genomic variations influencing disease susceptibility and drug response, aiming to refine therapeutic interventions.
Brad Margus co-founded Perlegen in early 2000, alongside Stanford professor David Cox, M.D., Ph.D., and Stephen Foder, Ph.D., a pioneer in microarray technology. Margus’s personal experience with his sons’ rare genetic disease informed its mission. This conviction, coupled with the emerging genomics landscape, provided the foundational insight that genetic understanding transforms patient care.
Perlegen serves pharmaceutical companies and clinicians by providing genetic insights for drug development and personalized treatment. Its vision centers on leveraging genomic data to predict individual responses to medicines, screen for side effects, and improve patient outcomes. The company integrates genetic information into clinical practice, guiding more effective therapeutic choices.
Key people at Perlegen Sciences.
Perlegen Sciences was a biotechnology company founded in 2000 focused on identifying patterns of genetic variation between individuals to improve patient care and uncover genetic foundations of diseases.[1][4][5] It specialized in human genomics research, participating in projects like the International HapMap Project, and developed genotyping protocols using Affymetrix oligonucleotide arrays for high-throughput analysis.[1] The company served pharmaceutical and research sectors by advancing pharmacogenomics and disease genetics but ceased operations on October 30, 2009, with no evident growth momentum post-closure.[1][2]
Perlegen Sciences was founded in late 2000 by David R. Cox, a key figure in genomics, with the initial mission to map genetic variations for medical applications.[1][4][5] The idea emerged amid the post-Human Genome Project era, emphasizing high-resolution genotyping to study individual differences.[1][3] Early traction included active involvement in the International HapMap Project, developing protocols for multiplexing PCR-amplified DNA on custom arrays, which positioned it as an innovator in biotech research before its 2009 closure.[1]
Perlegen rode the early 2000s genomics boom following the Human Genome Project, capitalizing on falling sequencing costs and demand for high-throughput variation mapping.[1][3] Its timing aligned with the rise of personalized medicine and pharmacogenomics, where identifying SNPs via HapMap data accelerated drug discovery and disease association studies.[1][4] Market forces like biotech investments in California (Mountain View base) favored it, influencing the ecosystem by providing foundational data and protocols still referenced in NCBI resources.[1][6] Though defunct, its work advanced tools now integral to modern genomics platforms.
Perlegen Sciences exemplified early genomics ambition but folded in 2009 amid biotech funding challenges, leaving a legacy in variation mapping rather than ongoing operations.[1][2] No revival appears likely given its closure over 15 years ago; instead, its innovations persist through open datasets like HapMap, shaping trends in precision medicine and AI-driven genomics. Its influence endures indirectly via successor technologies, underscoring how pioneering biotech firms fuel long-term ecosystem progress despite short lifespans.[1]
